Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

Inclusion Criteria: * Acute myeloid leukemia who fail to achieve complete remission with one course of induction chemotherapy or after relapse; patients must have less than 20% bone marrow or peripheral blood blasts * Acute myeloid leukemia in first remission with any of the following high risk features defined as: * Adverse cytogenetics: -5, deletion (del) 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8 or complex karyotype (\> 3 abnormalities) * Preceding myelodysplastic or myeloproliferative syndrome * Presence of high risk molecular abnormalities including FLT3 mutations, DNMT3A, TET2; ras; kit * French-American-British (FAB) monosomy (M)6 or M7 classification * Treatment related acute myeloid leukemia (AML) * Residual cytogenetic or molecular abnormalities * Myelodysplastic syndromes with intermediate, high or very high risk Revised International Prognostic Scoring System (R-IPSS) score, chronic myelomonocytic leukemia (CMML) or therapy related myelodysplastic syndromes (MDS) * Chronic myeloid leukemia (CML) which: * Failed to achieve a cytogenetic remission to tyrosine kinase inhibitor treatment or has a cytogenetic relapse * Has ever been in accelerated phase or blast crisis * Patient must have an identified HLA (A,B,C,DR) compatible related or unrelated donor who is age 16 years of age or older and weighs at least 110 pounds for the stem cell donation * Zubrod performance status 0 to 2 or Karnofsky of at least 60 * Left ventricu…